JP7126270B2 - Ｎｐｒａアゴニスト、組成物およびその使用 - Google Patents

Ｎｐｒａアゴニスト、組成物およびその使用 Download PDF

Info

Publication number
JP7126270B2
JP7126270B2 JP2019551608A JP2019551608A JP7126270B2 JP 7126270 B2 JP7126270 B2 JP 7126270B2 JP 2019551608 A JP2019551608 A JP 2019551608A JP 2019551608 A JP2019551608 A JP 2019551608A JP 7126270 B2 JP7126270 B2 JP 7126270B2
Authority
JP
Japan
Prior art keywords
seq
peptide
cgmp
composition
natriuretic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019551608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511494A5 (enExample
JP2020511494A (ja
Inventor
ジェラルド エム． カスティロ，
アシュフィールド 晶子 西本
エライジャー ボロティン，
Original Assignee
ファーマイン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマイン コーポレイション filed Critical ファーマイン コーポレイション
Publication of JP2020511494A publication Critical patent/JP2020511494A/ja
Publication of JP2020511494A5 publication Critical patent/JP2020511494A5/ja
Priority to JP2022070710A priority Critical patent/JP2022090049A/ja
Application granted granted Critical
Publication of JP7126270B2 publication Critical patent/JP7126270B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2019551608A 2017-03-22 2018-03-21 Ｎｐｒａアゴニスト、組成物およびその使用 Active JP7126270B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022070710A JP2022090049A (ja) 2017-03-22 2022-04-22 Ｎｐｒａアゴニスト、組成物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762475147P 2017-03-22 2017-03-22
US62/475,147 2017-03-22
PCT/US2018/023491 WO2018175534A1 (en) 2017-03-22 2018-03-21 Npra agonists, compositions, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022070710A Division JP2022090049A (ja) 2017-03-22 2022-04-22 Ｎｐｒａアゴニスト、組成物およびその使用

Publications (3)

Publication Number Publication Date
JP2020511494A JP2020511494A (ja) 2020-04-16
JP2020511494A5 JP2020511494A5 (enExample) 2021-04-01
JP7126270B2 true JP7126270B2 (ja) 2022-08-26

Family

ID=63585777

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019551608A Active JP7126270B2 (ja) 2017-03-22 2018-03-21 Ｎｐｒａアゴニスト、組成物およびその使用
JP2022070710A Withdrawn JP2022090049A (ja) 2017-03-22 2022-04-22 Ｎｐｒａアゴニスト、組成物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022070710A Withdrawn JP2022090049A (ja) 2017-03-22 2022-04-22 Ｎｐｒａアゴニスト、組成物およびその使用

Country Status (15)

Country Link
US (1) US20200017567A1 (enExample)
EP (1) EP3601314A4 (enExample)
JP (2) JP7126270B2 (enExample)
KR (1) KR102714599B1 (enExample)
CN (1) CN110603260B (enExample)
AU (2) AU2018239352A1 (enExample)
BR (1) BR112019019720A2 (enExample)
CA (1) CA3056433A1 (enExample)
EA (1) EA201992226A1 (enExample)
IL (1) IL269388B2 (enExample)
MX (1) MX2019010960A (enExample)
MY (1) MY201165A (enExample)
PH (1) PH12019550163A1 (enExample)
SG (1) SG11201908580XA (enExample)
WO (1) WO2018175534A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972590A4 (en) * 2019-05-22 2023-06-14 Merck Sharp & Dohme LLC NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USED TO TREAT CARDIOMETABOLIC DISEASES, KIDNEY DISEASES AND DIABETES
US20220281886A1 (en) 2019-05-22 2022-09-08 Merck Sharp Dohme Corp. Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
US20230416328A1 (en) * 2020-06-12 2023-12-28 Hirofumi Tachibana C-Type Natriuretic Peptides and Methods Thereof in Treating Acute Lung Injury
IL298992A (en) * 2020-06-12 2023-02-01 Pharmain Corp C-type natriuretic peptides and their methods for cancer treatment
CN120435308A (zh) 2022-10-21 2025-08-05 伊莱利利公司 长效利尿钠肽及其用途
AR130935A1 (es) 2022-11-02 2025-02-05 Novo Nordisk As Compuestos de cnp

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042472A1 (en) 1998-02-19 1999-08-26 Igen International, Inc. Heat shock fusion-based vaccine system
US20150307578A1 (en) 2007-08-03 2015-10-29 Pharmain Corporation Composition for long-acting peptide analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985722A (en) * 1973-12-12 1976-10-12 Ajinomoto Co., Inc. Process for preparing N-higher aliphatic acyl derivatives of amino acids, peptides or proteins
FR2687156B1 (fr) * 1992-02-12 1994-04-01 Roussel Uclaf Nouveaux derives peptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives.
CN1062311C (zh) * 1996-12-27 2001-02-21 中国医学科学院基础医学研究所 人白细胞介素2衍生物与人心钠素衍生物的融合基因、其蛋白产物及应用
JP4237375B2 (ja) * 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
DE60331584D1 (de) * 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
EP2162464A1 (en) * 2007-06-06 2010-03-17 Boehringer Ingelheim International GmbH Natriuretic fusion proteins
BRPI0815416A2 (pt) * 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
BRPI0904622A2 (pt) * 2008-05-23 2016-06-21 Asubio Pharma Co Ltd peptídeo com ação de prolongar a meia-vida de um peptídeo de interesse no plasma
HRP20161739T1 (hr) * 2009-05-20 2017-03-10 Biomarin Pharmaceutical Inc. VARIJANTE NATRIURETIČNOG PEPTIDA C-tipa
CA2823066A1 (en) * 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
EP2678025B1 (en) * 2011-02-23 2017-03-08 Madeleine Pharmaceuticals Pty Ltd Vsdl for use in the treatment of acute decompensated congestive heart failure
US20120220528A1 (en) * 2011-02-25 2012-08-30 Medtronic, Inc. Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042472A1 (en) 1998-02-19 1999-08-26 Igen International, Inc. Heat shock fusion-based vaccine system
US20150307578A1 (en) 2007-08-03 2015-10-29 Pharmain Corporation Composition for long-acting peptide analogs

Also Published As

Publication number Publication date
JP2022090049A (ja) 2022-06-16
CN110603260A (zh) 2019-12-20
EP3601314A1 (en) 2020-02-05
KR102714599B1 (ko) 2024-10-07
PH12019550163A1 (en) 2020-06-08
IL269388B2 (en) 2025-03-01
AU2025201270A1 (en) 2025-03-13
CN110603260B (zh) 2023-11-07
CA3056433A1 (en) 2018-09-27
MX2019010960A (es) 2020-01-20
SG11201908580XA (en) 2019-10-30
IL269388B1 (en) 2024-11-01
WO2018175534A1 (en) 2018-09-27
IL269388A (en) 2019-11-28
US20200017567A1 (en) 2020-01-16
BR112019019720A2 (pt) 2020-04-28
AU2018239352A1 (en) 2019-10-10
JP2020511494A (ja) 2020-04-16
EP3601314A4 (en) 2021-01-13
MY201165A (en) 2024-02-08
KR20190133201A (ko) 2019-12-02
EA201992226A1 (ru) 2020-02-12

Similar Documents

Publication Publication Date Title
JP7126270B2 (ja) Ｎｐｒａアゴニスト、組成物およびその使用
AU2021254623B2 (en) Long-acting adrenomedullin derivative
IL264864B2 (en) Amylin analogues
JPH08504823A (ja) エンドセリン拮抗薬
CN106164088B (zh) 长效肾上腺髓质素衍生物
Machado-Silva et al. Therapeutic uses for Angiotensin-(1-7)
IL272606B2 (en) Acylated oxyntomodulin peptide analog, pharmaceutical composition comprising same and uses thereof
EA044180B1 (ru) Агонисты npra, композиции и их использование
HK40017696A (en) Npra agonists, compositions, and uses thereof
HK40017696B (zh) Npra激动剂、组合物及其用途
KR20170069997A (ko) 미리스토일화된 렙틴-관련된 펩티드 및 이들의 용도
KR20130032787A (ko) 심혈관 질환 예방 및 치료용 펩타이드 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220808

R150 Certificate of patent or registration of utility model

Ref document number: 7126270

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250